Dermatological manifestations of Lyme borreliosis

European Journal of Dermatology

Volumn 14, Issue 5, 2004, Pages 296-309

  Müllegger, Robert R ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Acrodermatitis chronica atrophicans; Borrelia burgdorferi; Borrelial lymphocytoma; Erythema migrans; Human granulocytic ehrlichiosis; Lyme borreliosis

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; BACTERIAL VACCINE; CEFOTAXIME; CEFTRIAXONE; CEFUROXIME AXETIL; CYTOKINE; DOXYCYCLINE; LIPOPROTEIN A; MINOCYCLINE; PENICILLIN G; PENICILLIN V; TETRACYCLINE DERIVATIVE;

ACRODERMATITIS; BACTERIAL SKIN DISEASE; BORRELIA BURGDORFERI; CLINICAL TRIAL; DERMATOBORRELIOSIS; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA CHRONICUM MIGRANS; HISTOPATHOLOGY; HOST PATHOGEN INTERACTION; HOST RESISTANCE; HUMAN; LICHEN SCLEROSUS ET ATROPHICUS; LYME DISEASE; LYMPHOCYTOMA; PHOTOSENSITIVITY; POLYMERASE CHAIN REACTION; REVIEW; SCLERODERMA; SEROLOGY; SKIN LYMPHOMA;

ANIMALS; ANTI-BACTERIAL AGENTS; BORRELIA BURGDORFERI; HUMANS; LYME DISEASE; SKIN DISEASES, BACTERIAL; TICKS;

EID: 4544301283     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (174)

1. Aberer E, Stanek G, Ertl M, Neumann R. Evidence for spirochetal origin of circumscribed scleroderma (morphea). Acta Derm Venereol (Stockh) 1987; 67: 225-31.
2. Aberer E, Breier F, Stanek G, Schmidt B. Success and failure in the treatment of acrodermatitis chronica atrophicans. Infection 1996; 24: 85-7.
3. Aguero-Rosenfeld ME, Nowakowski J, Bittker S, Cooper D, Nadelman RB, Wormser GP. Evolution of the serologic response to Borrelia burgdorferi in treated patients with culture-confirmed erythema migrans. J Clin Microbiol 1996; 34: 1-9.
4. Aguero-Rosenfeld ME, Horowitz HW, Wormser GP, McKenna DF, Nowakowski J, Munoz J, Dumler JS. Human granulocytic ehrlichiosis: a case series from a medical center in New York State. Ann Intern Med 1996; 125: 904-8.
5. Akimoto S, Ishikawa O, Miyachi Y. The absence of antibodies against Borrelia burgdorferi in the sera of Japanese patients with localized scleroderma. J Rheumatol 1996; 23: 573-4.
6. Alonso-Llamazares J, Persing DH, Anda P, Gibson LE, Rutledge BJ, Iglesias L. No evidence for Borrelia burgdorferi infection in lesions of morphea and lichen sclerosus et atrophicus in Spain. A prospective study and literature review. Acta Derm Venereol (Stockh) 1997; 77: 299-304.
7. Arnez M, Radsel-Medvescek A, Pleterski-Rigler D, Ruzic-Sabljic E, Strle F. Comparison of cefuroxime axetil and phenoxymethyl penicillin for the treatment of children with solitary erythema migrans. Wien Klin Wochenschr 1999; 111: 916-22.
8. Arnez M, Pleterski-Rigler D, Ahcan J, Ruzic-Sabljic E, Strle F. Demographic features, clinical characteristics and laboratory findings in children with multiple erythema migrans in Slovenia. Wien Klin Wochenschr 2001; 113: 98-101.
9. Arnez M, Pleterski-Rigler D, Luznik-Bufon T, Ruzic-Sabljic E, Strle F. Solitary erythema migrans in children: comparison of treatment with azithromycin and phenoxymethyl penicillin. Wien Klin Wochenschr 2002; 114: 498-504.
10. Asbrink E. Erythema chronicum migrans Afzelius and acrodermatitis chronica atrophicans. Early and late manifestations of Ixodes ricinus-borne Borrelia spirochetes. Acta Derm Venereol (Stockh) 1985; (Suppl. 118): 1-63.
11. Asbrink E, Hovmark A, Hederstedt B. Serologic studies of erythema chronicum migrans Afzelius and acrodermatitis chronica atrophicans with indirect immunofluorescence and enzyme-linked immunosorbent assays. Acta Derm Venereol (Stockh) 1985; 65: 509-14.
12. Åsbrink E, Olsson I, Hovmark A. Erythema chronicum migrans Afzelius in Sweden. A study on 231 patients. Zentralbl Bakteriol 1986; 263: 229-36.
13. Åsbrink E, Hovmark A. Early and late cutaneous manifestations in Ixodes-borne borreliosis (erythema migrans borreliosis, Lyme borreliosis). Ann NY Acad Sci 1988; 539: 4-15.
14. Åsbrink E, Hovmark A, Olsson I. Lymphadenosis benigna cutis solitaria - borrelia lymphocytoma in Sweden. Zentralbl Bakteriol 1989; (Suppl. 18): 156-63.
15. Åsbrink E. Cutaneous manifestations of Lyme borreliosis. Clinical definitions and differential diagnoses. Scand J Infect Dis 1991; (Suppl. 77): 44-50.
16. Åsbrink E, Hovmark A, Weber K. Acrodermatitis chronica atrophicans, In: Weber K, Burgdorfer W, eds. Aspects of lyme borreliosis. Berlin, Heidelberg, New York: Springer; 1993. p. 193-204.
17. Bacon RM, Biggerstaff BJ, Schriefer ME, Gilmore Jr RD, Philipp MT, Steere AC, Wormser GP, Marques AR, Johnson BJ. Serodiagnosis of Lyme disease by kinetic enzyme-linked immunosorbent assay using recombinant VlsE1 or peptide antigens of Borrelia burgdorferi compared with 2-tiered testing using whole-cell lysates. J Infect Dis 2003; 187: 1187-99.
18. Bakken JS, Krueth J, Wilson-Nordskog C, Tilden RL, Asanovich K, Dumler JS. Clinical and laboratory characteristics of human granulocytic ehrlichiosis. JAMA 1996; 275: 199-205.
19. Baranton G, Postic D, Saint-Girons I, Boerlin P, Piffaretti JC, Assous M, Grimont PAD. Delineation of Borrelia burgdorferi sensu stricto, Borrelia garinii sp. nov. and group VS 461 associated with Lyme borreliosis. Int J Syst Bacteriol 1992; 42: 378-83.
20. Barsic B, Maretic T, Majerus L, Strugar J. Comparison of azithromycin and doxycycline in the treatment of erythema migrans. Infection 2000; 28: 153-6.
21. Batsford S, Rust C, Neubert U. Analysis of antibody response to the outer surface protein family in Lyme borreliosis patients. J Infect Dis 1998; 178: 1676-83.
22. Bennet L, Danell S, Berglund J. Clinical outcome of erythema migrans after treatment with phenoxymethyl penicillin. Scand J Infect Dis 2003; 35: 129-31.
23. Berglund J, Eitrem R, Norrby SR. Long-term study of Lyme borreliosis in a highly endemic area in Sweden. Scand J Infect Dis 1996; 28: 473-8.
24. Blanco JR, Oteo JA. Human granulocytic ehrlichiosis in Europe. Clin Microbiol Infect 2002; 8: 763-72.
25. Brehmer-Anderssan E, Hovmark A, Åsbrink E. Acrodermatitis chronica atrophicans: histopathologic findings and clinical correlations in 111 cases. Acta Derm Venereol (Stockh) 1998; 78: 207-13.
26. Breier F, Klade H, Stanek G, Poitschek C, Kirnbauer R, Dorda W, Aberer E. Lymphoproliferative responses to Borrelia burgdorferi in circumscribed scleroderma. Br J Dermatol 1996; 134: 285-91.
27. Breier F, Kunz G, Klade H, Stanek G, Aberer E. Erythema migrans: three weeks treatment for prevention of late Lyme borreliosis. Infection 1996; 24: 69-72.
28. Breier F, Khanakah G, Stanek G, Kunz G, Aberer E, Schmidt B, Tappeiner G. Isolation and polymerase chain reaction typing of Borrelia afzelii from a skin lesion in a seronegative patient with generalized ulcerating bullous lichen sclerosus et atrophicus. Br J Dermatol 2001; 144: 387-92.
29. Brettschneider S, Bruckbauer H, Klugbauer N, Hofmann H. Diagnostic value of PCR for detection of Borrelia burgdorferi in skin biopsy and urine samples from patients with skin borreliosis. J Clin Microbiol 1998; 36: 2658-65.
30. Buechner SA, Lautenschlager S, Itin P, Bircher A, Erb P. Lymphaproliferative responses to Borrelia burgdorferi in patients with erythema migrans, acrodermatitis chronica atrophicans, lymphadenosis benigna cutis, and morphea. Arch Dermatol 1995; 131: 673-7.
31. Carlsson SA, Granlund H, Jansson C, Nyman D, Wahlberg P. Characteristics of erythema migrans in Borrelia afzelii and Borrelia garinii infections. Scand J Infect Dis 2003; 35: 31-3.
32. Centers for Disease Control and Prevention. Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme disease. MMWR Morb Mortal Wkly Rep 1995; 44: 590-1.
33. Cerroni L, Zöchling N, Pütz B, Kerl H. Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma. J Cutan Pathol 1997; 24: 457-61.
34. Coyle PK. Advances and pitfalls in the diagnosis of Lyme disease. FEMS Immunol Med Microbial 1997; 19: 103-9.
35. Dattwyler RJ, Volkman DJ, Canaty SM, Platkin SP, Luft BJ. Amoxycillin plus probenecid versus doxycycline for treatment of erythema migrans borreliosis. Lancet 1990; 336: 1404-6.
36. Dattwyler RJ, Luft BJ, Kunkel MJ, Finkel MF, Wormser GP, Rush TJ, Grunwaldt E, Agger WA, Franklin M, Oswald D, Cockey L, Maladorno D. Ceftriaxone compared with doxycycline for the treatment of acute disseminated Lyme disease. N Engl J Med 1997; 337: 289-94.
37. De Koning J, Duray PH. Histopathology of human Lyme borreliosis, In: Weber K, Burgdorfer W, eds. Aspects of lyme borreliosis. Berlin, Heidelberg, New York: Springer; 1993. p. 70-92.
38. De Koning J, Tazelaar DJ, Hoogkamp-Korstanje JAA, Elema JD. Acrodermotitis chronica atrophicans: a light and electron microscopic study. J Cutan Pathol 1995; 22: 23-32.
39. Dennis DT, Hayes EB. Epidemiology of Lyme borreliosis, In: Gray J, Kahl O, Lane RS, Stanek G, eds. Lyme borreliosis. Biology, epidemiology and control. Oxon, New York: CABI Publishing; 2002. p. 251-80.
40. Dillon WI, Saed GM, Fivenson DP. Borrelia burgdorferi DNA is undetectable by polymerase choin reaction in skin lesions of morphea, scleroderma, or lichen sclerosus et atrophicus of patients from North America. J Am Acad Dermatol 1995; 33: 617-20.
41. Dumler JS, Dotevall L, Gustafson R, Granstrom M. A population-based seroepidemiologic study of human granulocytic ehrlichiosis and Lyme borreliosis on the west coast of Sweden. J Infect Dis 1997; 175: 720-2.
42. Ebnet K, Brown KD, Siebenlist UK, Simon MM, Shaw S. Borrelia burgdorferi activates nuclear factor-κB and is a potent inducer of chemotine and adhesion molecule gene expression in endothelial cells and fibroblasts. J Immunol 1997; 158: 3285-92.
43. Ekerfelt C, Ernerudh J, Bunikis J, Vrethem M, Aagesen J, Roberg M, Bergstrom S, Forsberg P. Compartmentalization of antigen specific cytokine responses to the central nervous system in CNS borreliosis: secretion of IFN-γ predominates over IL-4 secretion in response to outer surface proteins in Lyme disease Borrelia spirochetes. J Neuroimmunol 1997; 79: 155-62.
44. Eppes SC, Childs JA. Comparative study of cefuroxime axetil versus amoxicillin in children with early Lyme disease. Pediatrics 2002; 109: 1173-7.
45. Fagrell B, Stiernstedt G, Ostergren J. Acrodermatitis chronica otrophicans Herxheimer can often mimic a peripheral vascular disorder. Acta Med Scand 1986; 220: 485-8.
46. Feder Jr HM, Gerber MA, Luger SW, Ryan RW. Persistence of serum antibodies to Borrelia burgdorferi in patients treated for Lyme disease. Clin Infect Dis 1992; 15: 788-93.
47. Fingerle V, Goodman JL, Johnson RC, Kurtti TJ, Munderloh UG, Wilske B. Human granulocytic ehrlichiosis in southern Germany: increased seroprevalence in high-risk groups. J Clin Microbiol 1997; 35: 3244-7.
48. Fujiwara H, Fujiwara K, Hashimoto K, Mehregan AH, Schaumburg-Lever G, Lange R, Schempp C, Gollnick H. Detection of Borrelia burgdorferi DNA (B. garinii or B. afzelii) in morphea and lichen sclerosus et atrophicus tissues of German and Japanese but not of US patients. Arch Dermatol 1997; 133: 41-4.
49. Garcia-Monco JC, Benach JL. Lyme neuroborreliosis. Ann Neurol 1995; 37: 691-702.
50. Gasser R, Dusleag J, Reisinger E, Stauber R, Feigl B, Pongratz S, Klein W, Furian C, Pierer K. Reversal by ceftriaxone of dilated cardiomyopathy Borrelia burgdorferi infection. Lancet 1992; 339: 1174-5.
51. Glatz M. Charakterisierung der spezifischen Immuantwort gegen Borrelia burgdorferi beim Erythema migrans. Langzeit Follow-up Studie zu Verlauf und klinischer Relevanz an 113 Patienten. Austria: Thesis, Karl-Franzens-University Graz; 2003.
52. Goodman JL, Nelson CM, Vitale B, Madigan JE, Dumler JS, Kurtti TJ, Munderloh UG. Direct cultivation of the causative agent of human granulacytic ehrlichiosis. N Engl Med 1996; 334: 209-15.
53. Grange F, Wechsler J, Guillaume JC, Tortel MC, Audhuy B, Jaulhac B, Cerroni L. Borrelia burgdorferi-associated lymphocytoma cutis simulating a primary cutaneous large B-cell lymphoma. J Am Acad Dermatol 2002; 47: 530-4.
54. Granter SR, Barnhill RL, Hewins ME, Duray PH. Identification of Borrelia burgdorferi in diffuse fasciitis with peripheral eosinophilia: borrelial fasciitis. JAMA 1994; 272: 1283-5.
55. Gross DM, Steere AC, Huber BT. T helper 1 response is dominant and localized to the synovial fluid in patients with Lyme arthritis. J Immunol 1998; 160: 1022-8.
56. Guy EC, Robertson JN, Cimmino M, Gern L, Moosmann Y, Rijpkema SG, Sambri V, Stanek G. European interlaboratory comparison of Lyme borreliosis serology. Zentralbl Bakteriol 1998; 287: 241-7.
57. Hammers-Berggren S, Lebech AM, Karlsson M, Svenungsson B, Hansen K, Stiernstedt G. Serolagical follow-up after treatment of patients with erythema migrans and neuroborreliosis. J Clin Microbiol 1994; 32: 1519-25.
58. Harjacek M, Diaz-Cano S, Alman BA, Coburn J, Ruthazer R, Wolfe H, Steere AC. Prominent expression of mRNA for proinflammatory cytokines in synovium in potients with juvenile rheumatoid arthritis or chronic Lyme arthritis. J Rheumatol 2000; 27: 497-503.
59. Hashimoto Y, Takahashi H, Matsuo S, Hirai K, Takemori N, Nakao M, Miyamoto K, Iizuka H. Polymerose chain reaction of Borrelia burgdorferi flagellin gene in Shulman syndrome. Dermatology 1996; 192: 136-9.
60. Hoesly JM, Mertz LE, Winkelmann RK. Localized scleroderma (morphea) and antibody to Borrelia burgdorferi. J Am Acad Dermatol 1987; 17: 455-8.
61. Hofbauer GF, Kessler B, Kempf W, Nestle FO, Burg G, Dummer R. Multilesional primary cutaneous diffuse large B-cell lymphoma responsive to antibiotic treatment. Dermatology 2001; 203: 168-70.
62. Hovmark A, Åsbrink E, Olsson I. The spirochetal etiology of lymphadenosis benigna cutis solitaria. Acta Derm Venereol (Stockh) 1986; 66: 479-84.
63. Hulshof MM, Vandenbroucke JP, Nohlmans LM, Spanjaard L, Bavnick JN, Dijkmans BA. Long-term prognosis in patients treated for erythema chronicum migrans and acrodermatitis chronica atrophicans. Arch Dermatol 1997; 133: 33-7.
64. Hunfeld KP, Lambert A, Kampen H, Albert S, Epe C, Brade V, Tenter AM. Seroprevalence of Babesia infections in humans exposed to ticks in midwestern Germany. J Clin Microbiol 2002; 40: 2431-6.
65. Huppertz HI. Lyme disease in children. Curr Opin Rheumatol 2001; 13: 434-40.
66. Isogai E, Isogai H, Kimura K, Hayaski S, Kubota T, Nishikawa T, Natane A, Fujii N. Cytokines in me serum and brain in mice infected with distinct species of Lyme disease Borrelia. Microb Pathog 1996; 21: 413-9.
67. Jaulhac B, Heller R, Limbach FX, Hansmann Y, Lipsker D, Monteil H, Sibilia J, Piemont Y. Direct molecular typing of Borrelia burgdorferi sensu lato species in synovial samples from patients with Lyme arthritis. J Clin Microbiol 2000; 38: 1895-900.
68. Jelic S, Filipovic-Ljeskovic I. Positive serology for Lyme disease borrelias in primary cutaneous B-cell lymphoma: a study in 22 patients; is it fortuitous finding? Hematol Oncol 1999; 17: 107-16.
69. Kalish RA, McHugh G, Granquist J, Shea B, Ruthazer R, Steere AC. Persistence of immunoglobulin M or immunoglobulin G antibody responses to Borrelia burgdorferi 10-20 years after active Lyme disease. Clin Infect Dis 2001; 33: 780-5.
70. Kindstrand E, Nilsson BY, Hovmark A, Pirskanen R, Åsbrink E. Peripheral neuropathy in acrodermatitis chronica atrophicans - a late Barrelia manifestation. Acta Neurol Scand 1997; 95: 338-45.
71. Kindstrand E, Nilsson BY, Hovmark A, Pirskanen R, Åsbrink E. Peripheral neuropathy in acrodermatitis chronica atrophicans - effect of treatment. Acta Neurol Scand 2002; 106: 253-7.
72. Klempner MS, Hu LT, Evans J, Schmid CH, Johnson GM, Trevino RP, Norton D, Levy L, Wall D, McCall J, Kosinski M, Weinstein A. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med 2001; 345: 85-92.
73. Kraiczy P, Hellwage J, Skerka C, Becker H, Kirschfink M, Simon M, Brade V, Zipfel PF, Wallich R. Complement resistance of Borrelia burgdorferi correlates with the expression of BbCRASP-1, a novel linear plasmid-encoded surface protein that interacts with human factor H and FHL and is unrelated to Erp proteins. J Biol Chem 2004; 279: 2421-9.
74. Kuiper H, van Dam AP, Spanjaard L, de-Jongh BM, Widjojokusumo A, Ramselaar TC, Cairo I, Vos K, Dankert J. Isolation of Borrelia burgdorferi from biopsy specimens taken from healthy-looking skin of patients with Lyme borreliosis. J Clin Microbiol 1994; 32: 715-20.
75. Kutting B, Bonsmann G, Metze D, Luger TA, Cerroni L. Borrelia burgdorferi-associated primary cutaneous B cell lymphoma: complete clearing of skin lesions after antibiotic pulse therapy or intralesional injection of interferon alfa-2a. J Am Acad Dermatol 1997; 36: 311-4.
76. Lebech AM, Hansen K, Pancholi P, Sloan LM, Magera JM, Persing DH. Immunoserologic evidence of human granulocytic ehrlichiosis in Danish patients with Lyme neuroborreliosis. Scand J Infect Dis 1998; 30: 173-6.
77. Lebech AM, Hansen K, Bandrup F, Clemmensen O, Halkier-Sorensen L. Diagnostic value of PCR for detection of Borrelia burgdorferi DNA in clinical specimens from patients with erythema migrans and Lyme neuroborreliosis. Mol Diagn 2000; 5: 139-50.
78. Lebech AM. Polymerase chain reaction in diagnosis of Borrelia burgdorferi infections and studies on taxonomic classification. APMIS Suppl 2002; 105: 1-40.
79. Liang FT, Philipp MT. Analysis of antibody response to invariable regions of VIsE, the variable surface antigen of Borrelia burgdorferi. Infect Immun 1999; 67: 6702-6.
80. Liana FT, Steere AC, Marques AR, Johnson BJ, Miller JN, Philipp MT. Sensitive and specific serodiagnosis of Lyme disease by enzyme-linked immunosorbent assay with a peptide based on an immunodominant conserved region of Borrelia burgdorferi vlsE. J Clin Microbiol 1999; 37: 3990-6.
81. Liveris D, Wang G, Girao G, Byrne DW, Nowakowski J, McKenna D, Nadelman R, Wormser GP, Schwartz I. Quantitative detection of Borrelia burgdorferi in 2-millimeter skin samples of erythema migrans lesions: correlation of results with clinical and laboratory findings. J Clin Microbiol 2002; 40: 1249-53.
82. Lomholt H, Lebech AM, Hansen K, Bandrup F, Halkier-Sorensen L. Long-term serological follow-up of patients treated for chronic cutaneous borreliosis or culture-positive erythema migrans. Acta Derm Venereol (Stockh) 2000; 80: 362-6.
83. Luft BJ, Dattwyler RJ, Johnson RC, Luger SW, Bosler EM, Rahn DW, Masters EJ, Grunwaldt E, Gadgil SD. Azithromycin compared with amoxicillin in the treatment of erythema migrans. A double-blind, randomized, controlled trial. Ann Intern Med 1996; 124: 785-91.
84. Luger SW, Paparone P, Wormser GP, Nadelmon RB, Grunwaldt E, Gomez G, Wisniewski M, Collins JJ. Comparison of cefuroxime axetil and doxycycline in treatment of potients with early Lyme disease associated with erythema migrans. Antimicrob Agents Chemother 1995; 39: 661-7.
85. Ma Y, Weis JJ. Borrelia burgdorferi outer surface lipoproteins OspA and OspB posses B-cell mitogenic and cytokine stimulatory properties. Infect Immun 1993; 61: 3843-53.
86. Maraspin V, Lotric-Furlan S, Cimperman J, Ruzic-Sabljic E, Strle F. Erythema migrans in the immunocompromised host. Wien Klin Wochenschr 1999; 111: 923-32.
87. Maraspin V, Cimperman J, Lotric-Furlan S, Pleterski-Rigler D, Strle F. Erythema migrans in pregnancy. Wien Klin Wochenschr 1999; 111: 933-40.
88. Maraspin V, Ruzic-Sabljic E, Cimperman J, Lotric-Furlan S, Jurca T, Picken RN, Strle F. Isolation of Borrelia burgdorferi sensu lato from blood of patients with erythema migrans. Infection 2001; 29: 65-70.
89. Maraspin V, Cimperman J, Lotric-Furlan S, Ruzic-Sabljic E, Jurca T, Strle F. Cerebrospinal fluid findings in adult patients with multiple erythema migrans. Wien Klin Wochenschr 2002; 114: 505-9.
90. Maraspin V, Cimperman J, Lotric-Furlan S, Ruzic-Sabljic E, Jurca T, Picken R, Strle F. Solitary borrelial lymphocytoma in adult patients. Wien Klin Wochenschr 2002; 114: 515-23.
91. Marsch WC, Mayet A, Wolter M. Cutonaus fibroses induced by Borrelia burgdorferi. Br J Dermatol 1993; 128: 674-8.
92. Massarotti EM, Luger SW, Rahn DW, Messner RP, Wong JB, Johnson RC, Steere AC. Treatment of early Lyme disease. Am J Med 1992; 92: 396-403.
93. Mathiesen MJ, Hansen K, Axelsen N, Halkier-Sorensen L, Theisen M. Analysis of the human antibody response to outer surface protein C (OspC) of Borrelia burgdorferi sensu stricto, B. garinii, and B. afzelii. Med Microbiol Immunol (Berl) 1996; 185: 121-9.
94. Morrison TB, Weis JH, Weis JJ. Borrelia burgdorferi outer surface protein A (OspA) activates and primes human neutrophils. J Immunol 1997; 158: 4838-45.
95. Müllegger RR, Zöchling N, Soyer HP, Hödl S, Wienecke R, Volkenandt M, Kerl H. No detection of Borrelia burgdorferi-specific DNA in erythema migrans lesions after minocycline treatment. Arch Dermatol 1995; 131: 678-82.
96. Müllegger RR, Schlüpen EM, Millner MM, Soyer HP, Volkenandt M, Kerl H. Acrodermatitis chronica atrophicans in an 11-year-old girl. Br J Dermatol 1996; 135: 609-12.
97. Müllegger RR, Zöchling N, Schlüpen EM, Soyer HP, Hödl S, Kerl H, Volkenandt M. Polymerase chain reaction control of antibiotic treatment in dermatoborreliosis. Infection 1996; 24: 76-9.
98. Müllegger RR, McHugh G, Ruthazer R, Binder B, Kerl H, Steere AC. Differential expression of cytokine mRNA in skin specimens from patients with erythema migrans or acrodermatitis chronica atrophicans. J Invest Dermatol 2000; 115: 1115-23.
99. Müllegger RR. Clinical aspects and diagnosis of erythema migrans and borrelial lymphocytoma. Acta Dermatoven APA 2001; 10: 152-8.
100. Munksgaard L, Frisch M, Melbye M, Hjalgrim H. Incidence patterns of Lyme disease and cutaneous B-cell non-Hodgkin's lymphoma in the United States. Dermatology 2000; 201: 351-2.
101. Nadelman RB, Luger SW, Frank E, Wisniewski M, Collins JJ, Wormser GP. Comparison of cefuroxime axetil and doxycycline in the treatment af early Lyme disease. Ann Intern Med 1992; 117: 273-80.
102. Nadelman RB, Nowakowski J, Forseter G, Goldberg NS, Bittker S, Cooper D, Aguero-Rosenfeld M, Wormser GP. The clinical spectrum of early Lyme borreliosis in patients with culture-confirmed erythema migrans. Am J Med 1996; 100: 502-8.
103. Nadelman RB, Nowakowski J, Fish D, Falco RC, Freeman K, McKenna D, Welch P, Marcus R, Aguero-Rosenfeld ME, Dennis DT, Wormser GP. Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an Ixodes scapuloris tick bite. N Engl J Med 2001; 345: 79-84.
104. Nagi KS, Joshi R, Thakur RK. Cardiac manifestations of Lyme disease: a review. Can J Cardiol 1996; 12: 503-6.
105. Neumann R, Aberer E, Stanek G. Treatment and course of erythema chronicum migrans. Zentralbl Bakteriol 1987; 263: 372-6.
106. Nicholson WL, Comer JA, Sumner JW, Gingrich-Baker C, Coughlin RT, Magnarelli LA, Olson JG, Childs JE. An indirect immunofluorescence assay using cell culture-derived antigen for detection of antibodies to the agent of human granulocytic ehrlichiosis. J Clin Microbiol 1997; 35: 1510-6.
107. Nocton JJ, Dressier F, Rutledge BJ, Rys PN, Persing DH, Steere AC. Detection of Borrelia burgdorferi DNA by polymerase chain reaction in synovial fluid of patients with Lyme arthritis. N Engl J Med 1994; 330: 229-34.
108. Nowakowski J, Nadelman RB, Forseter G, McKenna D, Wormser GP. Doxycycline versus tetracycline therapy for Lyme disease associated with erythema migrans. J Am Acad Dermatol 1995; 32: 223-7.
109. Nowakowski J, Schwartz I, Liveris D, Wang G, Aguero-Rosenfeld ME, Girao G, McKenno D, Nadelman RB, Cavaliere LF, Wormser GP. Laboratory diagnostic techniques for patients with early Lyme disease associated with erythema migrans: a comparison of different techniques. Clin Infect Dis 2001; 33: 2023-7.
110. Nowakowski J, Nadelman RB, Sell R, McKenna D, Cavaliere LF, Holmgren D, Gaidici A, Wormser GP. Long-term follow-up of patients with culture-confirmed Lyme disease. Am J Med 2003; 115: 91-6.
111. O'Connel S, Granström M, Gray JS, Stanek G. Epidemiology of European Lyme borreliosis. Zentralbl Bakteriol 1998; 287: 229-40.
112. Oksi J, Savolainen J, Pène J, Bousquet J, Laippala P, Viljonen MK. Decreased interleukin-4 and increased gommo interferon production by peripheral blood mononuclear cells of patients with Lyme borreliosis. Infect Immun 1996; 64: 3620-3.
113. Oksi J, Marttila H, Soini H, Aho H, Uksila J, Viljanen MK. Eorly dissemination of Borrelia burgdorferi without generalized symptoms in patients with erythema migrans. APMIS 2001; 109: 581-8.
114. Olsson I, Åsbrink E, von-Stedingk M, von-Stedingk LV. Changes in Borrelia burgdorferi-specific serum IgG antibody levels in patients treated for acrodermatitis chronica atrophicans. Acta Derm Venereol (Stockh) 1994; 74: 424-8.
115. Orloski KA, Hayes EB, Campbell GL, Dennis DT. Surveillance for Lyme disease - United States, 1992-1998. MMWR CDC Surveill Summ 2000; 49: 1-11.
116. Ornstein K, Berglund J, Nilsson I, Norrby R, Bergstrom S. Characterization of Lyme borreliosis isolates from patients with erythema migrans and neuroborreliosis in southern Sweden. J Clin Microbiol 2001; 39: 1294-8.
117. Panelius J, Lahdenne P, Heikkila T, Peltomaa M, Oksi J, Seppala I. Recombinant OspC from Borrelia burgdorferi sensu stricto, B. afzelii, and B. garinii in the serodiagnosis of Lyme borreliosis. J Med Microbiol 2002; 51: 731-9.
118. Petrovec M, Lotric FS, Zupanc TA, Strle F, Brouqui P, Roux V, Dumler JS. Human disease in Europe caused by a granulocytic Ehrlichia species. J Clin Microbiol 1997; 35: 1556-9.
119. Picken MM, Picken RN, Han D, Cheng Y, Ruzic-Sabljic E, Cimperman J, Maraspin V, Lotric Furlan S, Strle F. A two-year prospective study to compare culture and polymerase chain reaction amplification for the detection and diagnosis of Lyme borreliosis. Mol Pathol 1997; 50: 186-93.
120. Picken RN, Strle F, Ruzic-Sabljic E, Maraspin V, Lotric-Furlan S, Cimperman J, Cheng Y, Picken MM. Molecular subtyping of Borrelia burgdorferi sensu lato isolates from five patients with solitary lymphocytoma. J Invest Dermatol 1997; 108: 92-7.
121. Picken RN, Strle F, Picken MM, Ruzic Sabljic E, Maraspin V, Lotric Furlan S, Cimperman J. Identification of three species of Borrelia burgdorferi sensu lato (B. burgdorferi sensu stricto, B. garinii, and B. afzelii) among isolates from acrodermatitis chronica atrophicans lesions. J Invest Dermatol 1998; 110: 211-4.
122. Radolf JD, Arndt LL, Akins DR, Jones JD, Rush J, Slaughter CA, Radolf J, Norgard MV. Treponema pallidum and Borrelia burgdorferi lipoproteins and synthetic lipopeptides activate monocytes/macrophages. J Immunol 1995; 154: 2866-77.
123. Raguin G, Boisnic S, Souteyrand P, Baranton G, Piette JC, Godeau P, Frances C. No evidence for a spirochetal origin of localized scleroderma. Br J Dermatol 1992; 127: 218-20.
124. Robertson J, Guy E, Andrews N, Wilske B, Anda P, Granstrom M, Hauser U, Moosmann Y, Sambri V, Schelkens J, Stonek G, Gray J. A European multicenter study of immunoblotting in serodiagnosis of Lyme borreliosis. J Clin Microbiol 2000; 38: 2079-102.
125. Rass SA, Sanchez JL, Tabaas JO. Spirachetal farms in the dermal lesions of morphea and lichen sclerosus et atrophicus. Am J Dermatopathol 1990; 12: 357-62.
126. Schempp C, Bocklage H, Lange R, Kolmel HW, Orfanos CE, Gollnick H. Further evidence for Borrelia burgdorferi infection in morphea and lichen sclerosus et atrophicus confirmed by DNA amplification. J Invest Dermatol 1993; 100: 717-20.
127. Schoenfeld R, Araneo B, Ma Y, Yang LM, Weiss JJ. Demonstration of a B-lymphocyte mitogen produced by the Lyme disease pathogen, Borrelia burgdorferi. Infect Immun 1992; 60: 455-64.
128. Seiler KP, Weiss JJ. Immunity to Lyme disease: protection, pathology and persistence. Curr Opin Immunol 1996; 8: 503-9.
129. Shapiro ED. Doxycycline for tick bites - not for everyone. N Engl J Med 2001; 345: 133-4.
130. Sigal LH, Zahradnik JM, Lavin P, Patella SJ, Bryant G, Haselby R, Hilton E, Kunkel M, Adler-Klein D, Doherty T, Evans J, Malawista SE, the Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium. A vaccine consisting of recombinant Borrelia burgdorferi outer surface protein A to prevent Lyme disease. N Engl J Med 1998; 339: 216-22.
131. Smith RP, Schoen RT, Rahn DW, Sikand VK, Nowakowski J, Parenti DL, Holman MS, Persing DH, Steere AC. Clinical characteristics and treatment outcome of early Lyme disease in patients with microbiologically confirmed erythema migrans. Ann Intern Med 2002; 136: 421-8.
132. Spach DH, Shimada JK, Paauw DS. Localized alopecia at the site of erythema migrans. J Am Acad Dermatol 1992; 27: 1023-4.
133. Stanek G. Lyme borreliosis. Wien Med Wschr 1995; 145: 155-61.
134. Stanek G, O'Connell S, Cimmino M, Aberer E, Kriostoferitsch W, Granstrom M, Guy E, Gray J. European Union Concerted Action on risk assessment in Lyme borreliosis: clinical case definitions for Lyme borreliosis. Wien Klin Wochenschr 1996; 108: 741-7.
135. Steere AC, Hutchinson GJ, Rahn DW, Sigal LH, Croft JE, DeSonno ET, Malowista SE. Treatment of the early manifestations of Lyme disease. Ann Intern Med 1983; 99: 22-6.
136. Steere AC, Bartenhagen NH, Craft JE, Hutchinson GJ, Newman JH, Rahn DW, Sigal LH, Spieler PN, Stenn KS, Malawisto SE. The early clinical manifestations of Lyme disease. Ann Intern Med 1983; 99: 76-82.
137. Steere AC, Sikand VK, Meurice F, Parenti DL, Fikrig E, Schoen RT, Nowakowski J, Schmid CH, Laukamp S, Buscorino C, Krause DS, the Lyme disease Vaccine Study Group. Vaccination ogainst Lyme disease with recombinant Borrelia burgdorferi outer surface lipoprotein A with adjuvant. N Engl J Med 1998; 339: 209-15.
138. Steere AC. Lyme disease. N Engl J Med 2001; 345: 115-25.
139. Steere AC, McHugh G, Suarez C, Hoitt J, Damle N, Sikand VK. Prospective study of coinfection in patients with erythema migrons. Clin Infect Dis 2003; 36: 1078-81.
140. Strle F, Ruzic E, Cimperman J. Erythema migrans: comparison of treatment with azithromycin, doxycycline, and phenoxymethyl penicillin. J Antimicrob Chemother 1992; 30: 543-50.
141. Strle F, Moraspin V, Furlan-Lotric S, Cimperman J. Epidemiological study of a cohort of adult patients with erythema migrans registered in Slovenia in 1993. Eur J Epidemiol 1996; 12: 503-7.
142. Strle F, Nelson JA, Ruzic-Sabljic E, Cimperman J, Maraspin V, Lotric-Furlan S, Cheng Y, Picken MM, Trenholme GM, Picken RN. European Lyme borreliosis: 231 culture-confirmed cases involving patients with erythema migrans. Clin Infect Dis 1996; 23: 61-5.
143. Strle F, Maraspin V, Lotric-Furlan S, Ruzic-Sabljic E, Cimperman J. Azithromycin and doxycycline for treatment of Borrelia culture-positive erythema migrans. Infection 1996; 24: 64-8.
144. Strle F, Maraspin V, Pleterski-Rigler D, Lotric-Furlan S, Ruzic-Sabljic E, Jurca T, Cimperman J. Treatment of borrelial lymphocytoma. Infection 1996; 24: 80-4.
145. Strle F, Nadelman RB, Cimperman J, Nowakowski J, Picken RN, Schwartz I, Maraspin V, Aguero-Rosenfeld ME, Varde S, Lotric-Furlan S, Wormser GP. Comparison of culture-confirmed erythema migrans caused by Borrelia burgdorferi sensu stricto in New York and by Borrelia afzelii in Slovenia. Ann Intern Med 1999; 130: 32-6.
146. Strle F, Videcnik J, Zorman P, Cimperman J, Lotric-Furlan S, Maraspin V. Clinical and epidemiological findings for patients with erythema migrans. Comparison of cohorts from the years 1993 and 2000. Wien Klin Wochenschr 2002; 114: 493-7.
147. Strobino BA, Abid S, Gewitz M. Maternal Lyme disease and congenital heart disease: a case-control study in an endemic area. Am J Obstet Gynecol 1999; 180: 711-6.
148. Van Dam AP, Kuiper H, Vos K, Widjojokusumo A, de Jongh BM, Spanjaard L, Ramselaar ACP, Kramer MD, Dankert J. Different genospecies of Borrelia burgdorferi are associated with distinct clinical manifestations of Lyme borreliasis. Clin Infect Dis 1993; 17: 708-17.
149. Van Dobbenburgh A, Van Dam AP, Fikrig E. Human granulocytic ehrlichiosis in Western Europe. N Enql J Med 1999; 340: 1214-6.
150. Von Stedingk LV, Olsson I, Hanson HS, Åsbrink E, Hovmark A. Polymerase chain reaction for detection of Borrelia burgdorferi DNA in skin lesions of early and late Lyme borreliosis. Eur J Clin Microbiol Infect Dis 1995; 14: 1-5.
151. Wang WZ, Fredrikson S, Sun JB, Link H. Lyme neuroborreliosis: evidence for persistent up-regulation of Borrelia burgdorferi-reactive cells secreting interferon-. Scand J Immunol 1995; 42: 694-700.
152. Wang G, van Dam AP, Spanjaard L, Dankert J. Molecular typing of Borrelia burgdorferi sensu lato by randomly amplified polymorphic DNA fingerprinting analysis. J Clin Microbiol 1998; 36: 768-76.
153. Wang G, van Dam AP, Schwartz I, Dankert J. Molecular typing of Borrelia burgdorferi sensu lato: taxonomic, epidemiological, and clinical implications. Clin Microbiol Rev 1999; 12: 633-53.
154. Warshafsky S, Nowakowski J, Nadelman RB, Kamer RS, Peterson SJ, Wormser GP. Efficacy of antibiotic prophylaxis for prevention of Lyme disease. J Gen Intern Med 1996; 11: 329-33.
155. Weber K, Schierz G, Wilske B, Preac-Mursic V. European erythema migrans disease and related disorders. Yale J Biol Med 1984; 57: 463-71.
156. Weber K, Neubert U. Clinical features of early erythema migrans disease and related disorders. Zentralbl Bokteriol 1986; 263: 209-28.
157. Weber K, Preac-Mursic V, Neubert U, Thurmayr R, Herzer P, Wilske B, Schierz G, Marget W. Antibiotic therapy of eorly European Lyme borreliosis and acrodermatitis chronica atrophicans. Ann NY Acad Sci 1988; 539: 324-45.
158. Weber K, Preac-Mursic V, Reimers CD. Spirochetes isolated from two
159. Weber K, Preac-Mursic V, Wilske B, Thurmayr R, Neubert U, Scherwitz C. A randomized trial of ceftriaxone versus oral penicillin for the treatment of eorly European Lyme borreliosis. Infection 1990; 18: 91-6.
160. Weber K, Wilske B, Preac-Mursic V, Thurmayr R. Azithromycin versus penicillin V for the treatment of early Lyme borreliosis. Infection 1993; 21: 367-72.
161. Weber K. Therapy of cutaneous manifestations, In: Weber K, Burgdorfer W editors. Aspects of lyme borreliosis. Berlin, Heidelberg, New York: Springer; 1993. p. 312-27.
162. Weber K, Pfister HW. Clinical management of Lyme borreliosis. Lancet 1994; 343: 1017-20.
163. Weger W, Müllegger RR. Histopathology and immunohistochemistry of dermatoborreliosis. Acta Dermatoven APA 2001; 10: 135-42.
164. Weide B, Schittek B, Klyscz T, Schuz K, Stark M, Rassner G, Wilske B, Garbe C. Morphoea is neither associated with features of Borrelia burgdorferi infection, nor is this agent detectable in lesional skin by polymerase chain reaction. Br J Dermatol 2000; 143: 780-5.
165. Weiss NL, Sadock VA, Sigal LH, Phillips M, Merryman PF, Abramson SB. False positive seroreactivity to Borrelia burgdorferi in systemic lupus erythematosus. The value of immunoblot analysis. Lupus 1995; 4: 131-7.
166. Wilske B, Preac-Mursic V. Microbiological diagnosis of Lyme borreliosis, In: Weber K, Burgdorfer W editors. Aspects of Lyme Borreliosis. Berlin, Heidelberg, New York: Springer; 1993. p. 267-99.
167. Wilske B, Fingerle V, Herzer P, Hofmann A, Lehnert G, Peters H, Pfister HW, Preac-Mursic V, Soutschek E, Weber K. Recombinant immunoblot in the serodiagnosis of Lyme borreliosis. Med Microbiol Immunol 1993; 182: 255-70.
168. Wong S, Grady LJ. Ehrlichia infection as a cause of severe respiratory distress. N Engl J Med 1996; 334: 273.
169. Wood GS, Kamath NV, Guitart J, Heald P, Kohler S, Smaller BR, Cerroni L. Absence of Borrelia burgdorferi DNA in cutaneous B-cell lymphomas from the United States. J Cutan Pathol 2001; 28: 502-7.
170. Wormser GP, Bittker S, Cooper D, Nowakowski J, Nadelman RB, Pavia C. Comparison of the yields of blood cultures using serum or plasma from patients with early Lyme disease. J Clin Microbiol 2000; 38: 1648-50.
171. Wormser GP, Nadelman RB, Dattwyler RJ, Dennis DT, Shapiro ED, Steere AC, Rush TJ, Rahn DW, Coyle PK, Persing DH, Fish D, Luft BJ. Practice guidelines for the treatment of Lyme disease. Clin Infect Dis 2000; 31 (Suppl. 1): 1-4.
172. Wormser GP, Ramanathan R, Nowakowski J, McKenna D, Holmgren D, Visintainer P, Dornbush R, Singh B, Nadelman RB. Duration of antibiotic therapy for early Lyme disease. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2003; 138: 697-704.
173. Yin Z, Braun J, Neure L, Wu P, Eggens U, Krause A, Kamradt T, Sieper J. T-cell cytokine pattern in joints of patients with Lyme arthritis and its regulation by cytokines and anticytokines. Arthritis Rheum 1997; 40: 69-79.
174. Zore A, Ruzic-Sabljic E, Maraspin V, Cimperman J, Lotric-Furlan S, Pikelj A, Jurca T, Logar M, Strle F. Sensitivity of culture and polymerase chain reaction for the etiologic diagnosis of erythema migrans. Wien Klin Wochenschr 2002; 114: 606-9.